CTBP2 antibody (full length)

Catalog No. ABIN7877732

This Mouse Monoclonal antibody specifically detects CTBP2 in IF and FACS. It exhibits reactivity toward Human.

Quick Overview for CTBP2 antibody (full length) (ABIN7877732)

Target: CTBP2 (C-terminal Binding Protein 2 (CTBP2))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CTBP2 antibody is un-conjugated

Application: Immunofluorescence (IF), Flow Cytometry (FACS)

Clone: PCRP-CTBP2-1A9

Product Details anti-CTBP2 Antibody

Binding Specificity: full length

Purpose: CTBP2 Antibody / C-terminal-binding protein 2

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human CTBP2 protein was used as the immunogen for the CTBP2 antibody.

Isotype: IgG2b

Application Details

Application Notes: Optimal dilution of the CTBP2 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the CTBP2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for CTBP2

Target: CTBP2 (C-terminal Binding Protein 2 (CTBP2))

Alternative Name: CTBP2

Background: The gene CTBP2 (C-terminal binding protein 2) encodes a member of the CtBP-family. The gene is mapped to human chromosome 21q21.3. It is found to be expressed ubiquitously, with higher expression in the heart, skeletal muscle, and pancreas. The gene CTBP2 (C-terminal binding protein 2) encodes a protein that functions as a transcriptional co-repressor of several tumor suppressor genes resulting in enhanced cancer cell migration and invasion. Its expression is found to be upregulated in hepatocellular carcinoma (HCC). It may be a potential prognostic marker for post liver resection HCC. It is involved in several types of tumor initiation, progression and response to therapy. It is found to interact with the C-terminal region of adenovirus type 2/5 E1A protein, a region that negatively regulates tumorigenicity and the extent of oncogenic transformation.

UniProt: P56545